Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Several studies have linked circulating cell-free mitochondrial DNA (ccf-mtDNA) to human disease. In particular, reduced ccf-mtDNA levels in the cerebrospinal fluid (CSF) of both Alzheimer’s and Parkinson’s disease (PD) patients have raised the hypothesis that ccf-mtDNA could be used as a biomarker for neurodegenerative disease onset and progression. However, how a reduction of CSF ccf-mtDNA levels relates to neurodegeneration remains unclear. Many factors are likely to influence ccf-mtDNA levels, such as concomitant therapeutic treatment and comorbidities. In this study we aimed to investigate these factors, quantifying CSF ccf-mtDNA from the Parkinson’s Progression Markers Initiative in 372 PD patients and 159 matched controls at two time points. We found that ccf-mtDNA levels appear significantly reduced in PD cases when compared to matched controls and are associated with cognitive impairment. However, our data indicate that this reduction in ccf-mtDNA is also associated with the commencement, type and duration of treatment. Additionally, we found that ccf-mtDNA levels are associated with comorbidities such as depression and insomnia, however this was only significant if measured in the absence of treatment. We conclude that in PD, similar to reports in HIV and sepsis, comorbidities and treatment can both influence ccf-mtDNA homeostasis, raising the possibility that ccf-mtDNA may be useful as a biomarker for treatment response or the development of secondary phenotypes. Given that, clinically, PD manifests often decades after neurodegeneration begins, predicting who will develop disease is important. Also, identifying patients who will respond to existing treatments or develop secondary phenotypes will have increased clinical importance as PD incidence rises.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Schwartz, M., & Baruch, K. (2014) · The EMBO Journal · doi:10.1002/embj.201386609 · Cited by 349
Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease
Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219
Kohler, C., Radpour, R., Barekati, Z., Asadollahi, R., Bitzer, J., Wight, E., Bürki, N., Diesch, C., Holzgreve, W., & Zhong, X. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-105 · Cited by 215
Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
Lindqvist, D., Wolkowitz, O. M., Picard, M., Ohlsson, L., Bersani, F. S., Fernström, J., Westrin, Å., Hough, C. M., Lin, J., Reus, V. I., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0001-9 · Cited by 188 · cited 4×
“Elevated plasma ccf-mtDNA levels are associated with nonresponsiveness to selective serotonin reuptake inhibitor (SSRI) treatment in major depressive disorder (MDD) [4] and vitamin C infusion has been shown to reduce plasma ccf-mtDNA levels in sepsis patients [25], suggesting that treatment may be an © The Author(s).”
BackgroundResultInfluentialBarrientos, A., Casademont, J., Cardellach, F., Estivill, X., Urbano-Marquez, A., & Nunes, V. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00278-7 · Cited by 149 · cited 1×
“In addition, L-dopa may affect the mtDNA pool available for release, as L-dopa can induce oxidative stress [31], affecting mitochondrial vitality and increasing cellular mtDNA copy-number in brains [32].”
BackgroundLevels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors
Zachariah, R. R., Schmid, S., Buerki, N., Radpour, R., Holzgreve, W., & Zhong, X. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181867bc0 · Cited by 142 · cited 3×
“Based on prior association [19], where mean log [10] ccf-mtDNA per microliter was 1.”
BackgroundMethodInfluential
Cited by
Mitochondrial DNA damage triggers spread of Parkinson’s disease-like pathology
Tresse, E., Marturia-Navarro, J., Sew, W. Q. G., Cisquella-Serra, M., Jaberi, E., Riera-Ponsati, L., Fauerby, N., Hu, E., Kretz, O., Aznar, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02251-4 · Cited by 99
The role of mitochondria in rheumatic diseases
Becker, Y. L. C., Duvvuri, B., Fortin, P. R., Lood, C., & Boilard, E. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00834-z · Cited by 81
Caicedo, A., Zambrano, K., Sanon, S., & Gavilanes, A. W. D. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.006 · Cited by 34
Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease
Lowes, H., Kurzawa-Akanbi, M., Pyle, A., & Hudson, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-72190-5 · Cited by 21
Self-citationZhang, Z., Qiu, X., Zeng, X., Liu, X., Lu, J., Xu, C., Huang, J., Zhao, C., & Zhan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-18650-2 · Cited by 6
Metadata
- Authors
- Lowes, H., Pyle, A., Santibanez-Koref, M., & Hudson, G.
- Venue
- Molecular Neurodegeneration
- Published
- 2020-02-18
- Volume
- 15
- Issue
- 1
- Pages
- 10-10
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W3012538260
- Cited by
- 91
- References
- 8
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment. https://app.cochat.ai/papers/10.1186/s13024-020-00362-y
- The paper
- Lowes, H., Pyle, A., Santibanez-Koref, M., & Hudson, G. (2020). Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-020-00362-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.